PATENT CLAIM ANALYSIS

Application Number: 16203654
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["424", "093210"]

Abstract:
Disclosed herein is a method for manufacturing a population of human insulin producing cells from non-pancreatic β-cells, wherein the resulting insulin producing cells have increased insulin content, or increased glucose regulated secretion of insulin, or a combination of both.

Claim (Index 22):
The method of  claim 1 , wherein at least 90% of said harvested transdifferentiated insulin producing cells express mesenchymal markers comprising CD29 or CD105 or CD90 or CD73 or CD44, or any combination thereof, and do not express CD45 or CD34 or CD14 or CD11b or CD19 or CD79, or any combination thereof, on their cell surface.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 98.0
- Lexical Diversity: 1.43333
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14983657', '14897262', '14330965', '10843801', '10113118']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7369962732973654
- 35 USC 102 Novelty (BERT): 0.6411439471188974
- Combined Prediction Score: 0.7274110406795186
- Mean Citation Score: 516.661872
- Max Citation Score: 831.7019700000003
- Similarity Product: 539.4034636811133

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test